Apr 9, 2016
Abpro Announces Partnership and Investment with Essex Bio for Development of Antibody Therapeutics
Abpro Announces Partnership and Investment with Essex Bio for Development of Antibody Therapeutics
APRIL 6, 2016
Abpro, a Massachusetts-based integrated life science company at the forefront of synthetic biology, has announced a partnership with Essex Bio, a biopharmaceutical company based in China. It has been agreed that Abpro and Essex will jointly develop multiple monoclonal antibodies in ophthalmology and immuno-oncology by leveraging the DiversImmune™ platform of Abpro. Moreover, as part…
View On WordPress